To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

May 27, 2020___

Today's Rundown

Featured Story

Gilead pens $2B Arcus pact for immuno-oncology targets of the past and future

Last month, rumors out of Bloomberg whispered that Gilead Sciences, more known for its COVID-19 work these days, was gearing up for a major stake in immuno-oncology player Arcus.

Top Stories

ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision

Last December, GlaxoSmithKline’s BCMA-targeting medicine shrank tumors in one-third of patients with advanced multiple myeloma, teeing up an FDA submission. Now, the antibody-drug conjugate is padding its case as the British drugmaker awaits the agency’s decision. The treatment's response rates stayed steady and it extended patients' lives by 15 months.

NGOs slam 'extremely dubious priorities' of EU R&D program

Nongovernmental organizations (NGOs) have accused the EU’s pharmaceutical research initiative of investing in “extremely dubious priorities.” The two NGOs think Big Pharma controls the agenda of the Innovative Medicines Initiative, leading it to prioritize areas that are profitable for drugmakers over public health needs.  

[Sponsored] How Treatment Technology is Advancing the Discovery of Cancer Medicines

Jazz Pharmaceuticals is applying its proprietary technology to recognize the potential of combination therapy for treating cancer patients and redefining what is possible in the treatment landscape.

The money keeps coming for Eli Lilly COVID-19 partner AbCellera with $105M round

Canadian biotech AbCellera has nabbed a meaty $105 million series B funding round as it looks to boost its antibody work and seek out new potential meds against COVID-19.

Q32 debuts with $46M to 'rebalance' innate and adaptive immunity

Many autoimmune diseases are treated with immunosuppressive drugs to rein in an immune system that has turned on the body’s own tissues. Problem is, that approach affects immune cells throughout the body. Enter Q32 Bio, which is working on a new generation of treatments for autoimmune and inflammatory diseases.

Siemens begins shipping coronavirus antibody tests with goal of 50M per month

While aiming to double its manufacturing capacity to more than 50 million blood tests per month, Siemens Healthineers has begun shipping its COVID-19 serology kits internationally, for use on about 20,000 analyzer systems installed worldwide.

Startup targets glioblastoma tumors with CAR-T therapy

Scientists at McMaster University and the University of Toronto have developed a CAR-T therapy targeting CD133 for aggressive brain cancer glioblastoma. The CAR-Ts are showing promise in mouse models, leading to the formation of a new biotech called Empirica Therapeutics.

What's needed to prove a COVID-19 vaccine works—and are top players across 3 continents there yet?

In the global hunt for COVID-19 vaccines, all developers are throwing enthusiasm around about their candidates. Critics say they're too optimistic. What do scientists really need to demonstrate before we can call a shot effective—and how far away are the leading candidates?

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

Resources

[Whitepaper] The Evolution and Importance of Biomedical Ontologies for Scientific Literature

Dive into the history of biomedical classification and how these systems have evolved to address new technology and use cases.

[Case Study] Establishing Parameters for Success

Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study.

[Fact Sheet] Forecasting to Optimize Clinical Trial Supply Management

Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study.

[eBook] Expecting the Unexpected: Strategies for Efficient Clinical Supply Management and Forecasting

Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study.

[Podcast] Developing residual HCPs ELISA assay for biopharmaceutical products

Listen to our brand-new Frontage Laboratories podcast where you’ll take home tips for developing residual host cell proteins ELISA assay for biopharmaceutical products using commercial kits.

[Virtual Event] Cardiac Safety London Online

Join us for a day of discovery as global experts in Cardiology, Pharmacology and Diabetes discuss state of the art methods in early phase clinical research.

[Whitepaper] The great data transition: Making the move from claims to EHR data

The immediacy of EHR data availability can be significantly impactful, particularly as the health care system works to address COVID-19. Download this whitepaper to learn more.

[Report] Decentralized Trials - Where Does the Industry Stand?

Patient-facing digital technologies are playing an important role in clinical trials for new drugs and medical devices, to the point where conducting virtual trials is becoming mainstream. But terms like remote trials, direct-to-patient trials, hybrid trials, decentralized trials, and more all add to the confusion of what makes a trial "virtual."

[Whitepaper] Why Your Business Needs An Effective Cloud Strategy To Survive Now

Businesses must maintain pre-pandemic levels of productivity with smaller IT budgets. Learn why an effective Cloud Strategy is imperative for success in these unprecedented times.

[Webinar] Optimizing your excipient screening for vaccine formulation

You are invited to join Rousselot Biomedical for an insightful webinar on excipients for vaccine formulation. Highly purified gelatins can help accelerate vaccine development.

[Whitepaper] Continuous Manufacturing vs Batch: Deciding on the Best Solution for your Oral Solid Dose Product

Continuous Manufacturing vs. Batch for Oral Solid Dose

[Whitepaper] Flexible Design for Novel Trials

Download this case study to read about how Cenduit navigated these challenges, and successfully supports the trial sponsor to execute the umbrella trial with agility.

[Whitepaper] Critical API Attributes and the Major Impact They Can Have on Drug Product Development

Download this whitepaper to learn more about the importance of an integrated approach to formulation.

[Case Study] More Powerful Analytics Capabilities

Case Study: Oncology-focused pharmaceutical company strengthens product launch by identifying hundreds of high-value physicians with Acorn AI.

[Case Study] Precision Analytics for Product Launch and Growth

Pharma launch teams spend significant resources on data and analytics with limited ROI. Read this case study to learn how a Life Sciences company identified two times more patients best suited for therapy, using Clarify’s deep and longitudinal patient and HCP insights. 

[Whitepaper] Is Wurster Processing the Right Choice for My Multiparticulate Modified Release Dosage Form?

Wurster processing is a versatile technique for developing and manufacturing multiparticulates for modified release dosage forms. Read this whitepaper to determine whether Wurster processing is the right option for your project.

[Webinar] Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

In this webinar, the featured speaker will explore the key advances and critical hurdles for translating these emerging molecular biology technologies into real-world applications and commercial processes.

[Whitepaper] Assessing the Financial Impact of Translational Pharmaceutics®

Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug. Download the whitepaper.

[Whitepaper] New Lonza Whitepaper on Modulating lgG Effector Function

This whitepaper summarises approaches for modulating antibody effector functions and pharmacokinetics, and provides examples of antibodies in clinical studies.

[GUIDE] Managing Clinical Trial Patient & Site Engagement During COVID-19

Leverage strategic solutions to respond to immediate challenges to patient and site engagement from COVID-19, and learn to maximize the FDA guidance on the conduct of clinical trials during a pandemic.

Events